Taltz (ixekizumab) / Eli Lilly, Japan Tobacco - LARVOL DELTA

Classic Hodgkin lymphoma in a patient treated with ixekizumab for generalized pustular psoriasis. (PubMed, Eur J Dermatol) - No abstract available

Journal • Classical Hodgkin Lymphoma • Dermatology • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Oncology • Psoriasis • Pustular Psoriasis

Cystic Lung Disease in Patients With Psoriasis or Psoriatic Arthritis (CAP 2025) - "One patient received a 5-day course of steroids prior to biopsy, and another had a 15-year treatment history (etanercept/ixekizumab). Some patients with psoriasis/psoriatic arthritis may develop cystic lung disease radiologically and histologically consistent with lymphoid interstitial pneumonia."

Clinical • Dermatology • Fibrosis • Hematological Malignancies • Immunology • Infectious Disease • Inflammatory Arthritis • Interstitial Lung Disease • Lymphoma • Pneumonia • Psoriasis • Psoriatic Arthritis • Pulmonary Disease • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies

Time to Onset of Action for Biologics and Targeted Treatments in Psoriasis: Systematic Targeted Literature Review and Network Meta-Analysis. (PubMed, Dermatol Ther (Heidelb)) - "IL-17 inhibitors, followed by IL-23 inhibitors, have the most rapid TOA among PsO biologics evaluated; any differences in onset of action between specific agents within the same drug class are not statistically or clinically significant. These analyses will allow clinicians to make more informed treatment decisions for their patients."

Journal • Retrospective data • Dermatology • Immunology • Psoriasis • IL12A • IL17A • IL23A

Efficacy and survival probability of patients with psoriasis treated with IL-17 inhibitors - bimekizumab, brodalumab, ixekizumab, and secukinumab: Real-world data from the Czech Republic BIOREP registry (EADV 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Psoriasis • IL17A

Quantifying the Role of Specialty Medications in Medicare Part D Expenditures in Dermatology. (PubMed, JAMA Dermatol) - "New therapies approved after 2013 (Otezla, Cosentyx, Taltz, Dupixent, Tremfya, Skyrizi, and Odomzo) accounted for 69.5% of all spending growth. Prescription rates increased more slowly for older specialty drugs (Humira, Enbrel, Stelara, and Erivedge), but their prices increased more (9.2% annually) than prices for newer agents...While the price of the average dermatologic medication has increased rapidly, this primarily reflects increased prescribing of newly introduced specialty drugs. While these therapies expand treatment options, their rising share of costs highlights the need for policies that balance innovation, access, and affordability."

Journal • Medicare • Reimbursement • US reimbursement • Dermatology

Comparative Effectiveness and Durability of Biologics Through 24 Months for Patients with Moderate-to-Severe Psoriasis: Results from the International, Observational Psoriasis Study of Health Outcomes (PSoHO). (PubMed, Dermatol Ther (Heidelb)) - "This study provides valuable real-world data on the long-term effectiveness and durability of biologic treatments for PsO, emphasizing the advantages of anti-IL-17A biologics, particularly IXE, in achieving and maintaining therapeutic responses. These findings support dermatologists in making informed decisions regarding PsO treatment strategies."

HEOR • Journal • Dermatology • Immunology • Oncology • Psoriasis • IL12A • IL17A • IL23A

Taltz - opinion on variation to marketing authorisation (European Medicines Agency) - "On 24 July 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Taltz. The marketing authorisation holder for this medicinal product is Eli Lilly and Co (Ireland) Limited. The CHMP adopted a new indication as follows: Juvenile idiopathic arthritis (JIA); Juvenile psoriatic arthritis (JPsA)."

CHMP • Idiopathic Arthritis • Psoriatic Arthritis

Real-world use of biologic and targeted synthetic disease-modifying antirheumatic drugs in US patients with psoriatic arthritis: Persistence, patient characteristics associated with discontinuation, and dosing patterns. (PubMed, J Manag Care Spec Pharm) - "Secondary objectives included (1) describing the factors associated with b/tsDMARD persistence or nonpersistence and (2) assessing maintenance dose changes among patients with PsA initiating the anti-IL17A agents secukinumab (SEC) or ixekizumab (IXE). Of patients initiating IXE therapy included in the analysis, 84.4% were prescribed an 80-mg Q4W starting maintenance dose and 10.4% were prescribed a 160-mg Q4W starting maintenance dose. The findings of this study provide relevant insights into tailoring b/tsDMARD therapy to maximize clinical benefit and potentially identify patients with the greatest unmet need."

Journal • Observational data • Real-world evidence • Retrospective data • Dermatology • Fatigue • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Patient Characteristics and Biologic Treatment History of Chinese Patients Receiving Ixekizumab for moderate to severe psoriasis: A Real-World Retrospective Analysis (EADV 2025) - No abstract available

Real-world • Real-world evidence • Retrospective data • Dermatology • Immunology • Psoriasis

Real-World Evidence for Ixekizumab in the Treatment of Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis: Systematic Literature Review 2022-2023. (PubMed, Adv Ther) - "Real-world ixekizumab use for PsO and PsA is effective and safe, with a positive impact on patient quality of life. More data are needed to draw conclusions for real-world ixekizumab use in axSpA."

HEOR • Journal • Real-world evidence • Review • Ankylosing Spondylitis • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • IL17A

Polymorphic Eruption and Lichen Planopilaris-Like Hair Loss Induced by Ixekizumab (EADV 2025) - No abstract available

Alopecia • Lichen Planus

Merkel cell carcinoma in a psoriasis patient on long-term ixekizumab therapy: A case report. (PubMed, SAGE Open Med Case Rep) - "Treatment with avelumab, chemotherapy, and radiotherapy led to partial remission, but 4 years later, he succumbed to the disease. Ixekizumab-associated immunosuppression may have contributed to Merkel cell carcinoma development, a tumor known to occur more frequently in immunocompromised individuals."

Journal • Dermatology • Immunology • Merkel Cell Carcinoma • Non-melanoma Skin Cancer • Oncology • Psoriasis • Skin Cancer • Solid Tumor

Ixekizumab improves disease severity and quality of life in patients with difficult-to-treat psoriasis: A 24-week real-life experience (EADV 2025) - No abstract available

Clinical • HEOR • Dermatology • Immunology • Psoriasis

Ixekizumab Improves Musculoskeletal Symptoms Measured by the IDEOM MSK-8 Questionnaire in Patients with Psoriasis and PEST Scores <3 or ≥3: Results From the Real-World Psoriasis in Special Areas (PSoSA) Study (EADV 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Musculoskeletal Diseases • Psoriasis

Assessment of the safety and efficacy of ixekizumab in patients with psoriasis: a single-centre retrospective study (EADV 2025) - No abstract available

Retrospective data • Dermatology • Immunology • Psoriasis

Unexplained Blepharitis Following Ixekizumab Therapy (EADV 2025) - No abstract available

Dry Eye Disease • Ocular Inflammation • Ophthalmology

Ixekizumab Demonstrates Continued Improvements in Nail and Scalp Psoriasis through 24 Weeks: Results from the Psoriasis in Special Areas (PSoSA) Study (EADV 2025) - No abstract available

Dermatology • Immunology • Psoriasis

Drug-induced Bullous Pemphigoid Following Ixekizumab Therapy: A Case Report (EADV 2025) - No abstract available

Case report • Clinical • Bullous Pemphigoid • Dermatology • Dermatopathology • Immunology

Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration. (PubMed, Adv Ther) - P3 | "Ixekizumab was shown to be efficacious in both patients with shorter or longer symptom duration and in r-axSpA or nr-axSpA."

HEOR • Journal • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Oncology • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis

Effectiveness of ixekizumab in 709 real-world patients with axial spondyloarthritis and psoriatic arthritis: a nationwide cohort study. (PubMed, RMD Open) - "In this nationwide observational study, ixekizumab was primarily prescribed in patients who had failed multiple biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), including other IL-17i. Retention rates were somewhat lower for axSpA than for PsA. For both axSpA and PsA, prior IL-17i treatment was associated with an increased risk of withdrawal, yet the relatively high retention rate and improvement in all disease activity outcomes suggest ixekizumab as a viable option for patients with multiple b/tsDMARD failures."

Journal • Observational data • Real-world evidence • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • IL17A

Discriminating capacity of the ASAS health index in patients with axial spondyloarthritis treated with ixekizumab. (PubMed, Semin Arthritis Rheum) - "Several ASAS HI improvement thresholds discriminated axSpA patients in treatment vs. placebo arms at Week 16. The ASAS HI ≥30% improvement threshold discriminated across all three COAST trials."

Journal • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Seronegative Spondyloarthropathies • Spondylarthritis

Ixekizumab and Malignant Neoplasms: A Pooled Analysis of Data From 25 Randomized Clinical Trials. (PubMed, JAMA Dermatol) - "This pooled analysis of 25 RCTs demonstrated that the safety profile of IXE supports long-term use in patients with PsO, PsA, or axSpA. This is evidenced by incidences of malignant neoplasms consistent with previous reports, and with SIRs of malignant neoplasms across indications similar to the US general population."

Clinical • Journal • Retrospective data • Ankylosing Spondylitis • Dermatology • Genetic Disorders • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Skin Cancer • Solid Tumor • Spondylarthritis

Risk of new-onset and recurrent uveitis with different biologics for ankylosing spondylitis: a network meta-analysis. (PubMed, Front Immunol) - "We conducted a network meta-analysis (NMA) to assess the impact of anti-TNF-α (adalimumab, etanercept, golimumab, and infliximab), IL-17 inhibitors (secukinumab, bimekizumab, and ixekizumab), and JAK inhibitors (tofacitinib and upadacitinib) on new-onset and recurrent uveitis. Inhibition of IL-17A (secukinumab and ixekizumab) alone might increase the risk of uveitis, while simultaneous inhibition of IL-17A and IL-17F (bimekizumab) significantly reduced the risk. Etanercept increased the risk of uveitis compared to other TNF-α inhibitors."

Clinical • Journal • Retrospective data • Review • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Ocular Inflammation • Ophthalmology • Rheumatology • Seronegative Spondyloarthropathies • Uveitis • IL17A

One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: Real-world data from the BIOBADASER registry. (PubMed, Reumatol Clin (Engl Ed)) - "In this real-world study, IXE showed an acceptable retention rate in patients with PsA and axSpA after one year of follow-up. Female sex and longer disease duration were associated with risk of withdrawal."

Journal • Observational data • Real-world evidence • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • IL17A

Cardiovascular and Kidney Outcomes After Systemic Treatment for Plaque Psoriasis: A Systematic Review and Network Meta-analysis. (PubMed, Dermatol Ther (Heidelb)) - "Bimekizumab showed better therapeutic efficacy scores and safety profile than other agents. Ixekizumab may increase cardiovascular risk and should be used with caution. Reliable long-term safety data of the treatments analyzed here require assessing non-randomized studies and examining postmarketing reports from regulatory agencies."

Clinical • Journal • Retrospective data • Cardiovascular • Dermatology • Immunology • Psoriasis